Outcomes of Cytoreduction and Oxaliplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Patients With Peritoneal Carcinomatosis From Colorectal Cancer

Among patients with metastatic colorectal cancer, 25% have isolated peritoneal carcinomatosis. We performed a systematic review and meta-analysis to assess the disease-free survival (DFS) and overall survival (OS) of patients undergoing hyperthermic intraperitoneal chemotherapy with oxaliplatin. Ele...

Descripción completa

Detalles Bibliográficos
Autores principales: Alhumaid, Moayad, Sait, Salma, Fallatah, Emad, AlSayegh, Nasser, Farsi, Ali, Nassif, Mohammed, Farsi, Nada J, Akeel, Nouf, Samkari, Ali, Shabkah, Alaa A, Trabulsi, Nora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
General Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579872/
https://www.ncbi.nlm.nih.gov/pubmed/34786251
http://dx.doi.org/10.7759/cureus.18670
Descripción
Sumario:Among patients with metastatic colorectal cancer, 25% have isolated peritoneal carcinomatosis. We performed a systematic review and meta-analysis to assess the disease-free survival (DFS) and overall survival (OS) of patients undergoing hyperthermic intraperitoneal chemotherapy with oxaliplatin. Eleven studies were included in the final assessment. Pooled three- and five-year OS rates were 58.60% and 42.19%, respectively. The estimated pooled three- and five-year DFS rates were 23.47% and 14.26%, respectively.

Ejemplares similares